PharmaDrug Inc. News Releases

PharmaDrug Completes Acquisition of Initial 19.9% Interest in Canurta Inc. and Completes Debt Restructuring

Mon, 05 Jan 2026 08:00:00 -0500

Toronto, Ontario--(Newsfile Corp. - January 5, 2026) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of natural medicines is pleased to announce that it has closed the previously announced (see press release dated October 31, 2025) acquisition (the "Transaction") of limited partnership units of Canurta Limited Partnership ("Canurta"), the parent entity of Canurta Inc., a...

PharmaDrug Announces Debt Restructuring

Fri, 31 Oct 2025 08:58:00 -0400

Toronto, Ontario--(Newsfile Corp. - October 31, 2025) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of natural medicines is pleased to announce that it has agreed to issue $445,686 principal amount of secured convertible debentures to two current holders of the Company's secured convertible debentures that were past their maturity date.Each Debenture will mature on...

PharmaDrug Signs Definitive Agreement to Acquire Equity Interest in Canurta Inc

Thu, 30 Oct 2025 09:00:00 -0400

Toronto, Ontario--(Newsfile Corp. - October 30, 2025) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of natural medicines is pleased to announce that it has executed a definitive securities exchange agreement (the "Definitive Agreement") with Canurta Limited Partnership ("Canurta") and each of the limited partners of Canurta, the parent entity of Canurta Inc., a...

PharmaDrug Inc.: Correction to News Release Dated July 30, 2025

Wed, 30 Jul 2025 11:37:00 -0400

Toronto, Ontario--(Newsfile Corp. - July 30, 2025) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), announces that the original news release captioned "PharmaDrug Signs LOI to Acquire Equity Interest in Canurta Inc." published on July 30, 2025 referred, incorrectly, to the number of common shares of PharmaDrug to be issued in the second tranche of the proposed transaction and the total number of shares to be issued pursuant to both tranches. The press release...

PharmaDrug Signs LOI to Acquire Equity Interest in Canurta Inc.

Wed, 30 Jul 2025 07:30:00 -0400

Toronto, Ontario--(Newsfile Corp. - July 30, 2025) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of natural medicines is announcing that it has entered into a non-binding Letter of Intent ("LOI") on July 23rd, 2025 to acquire up to a 40% equity interest in Canurta Limited Partnership ("Canurta"), the parent entity of Canurta Inc. (the "Transaction"), a biotechnology...

PharmaDrug Announces Resignation of Rob Steen as CEO and From Board of Directors

Mon, 16 Jun 2025 09:04:00 -0400

Toronto, Ontario--(Newsfile Corp. - June 16, 2025) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics and previously approved drugs, is announcing that Rob Steen has resigned as CEO and from the board of directors of the Company effective immediately. Chairman David Kideckel will step into the role of...

PharmaDrug Announces Strategic Review Process Intended to Maximize Shareholder Value

Fri, 06 Jun 2025 08:00:00 -0400

Toronto, Ontario--(Newsfile Corp. - June 6, 2025) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics and previously approved drugs, is announcing that the board of directors ("the Board") has formed a special committee of independent directors to lead a comprehensive strategic review process to consider...

PharmaDrug Announces Issuance of Debenture Units

Fri, 15 Nov 2024 17:30:00 -0500

Toronto, Ontario--(Newsfile Corp. - November 15, 2024) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines and naturally-derived approved drugs, is pleased to announce that further to its press release dated October 31, 2024, it has completed the issuance of $412,552.94 principal amount of debentures to replace currently...

PharmaDrug Announces Proposed Issuance of Debenture Units

Thu, 31 Oct 2024 17:55:00 -0400

Toronto, Ontario--(Newsfile Corp. - October 31, 2024) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics and naturally-derived approved drugs, is pleased to announce that it will be issuing $414,523 to replace currently outstanding secured convertible debentures and a total of 8,290,000 common share...

PharmaDrug's Sairiyo Therapeutics Announces Successful Completion of Stability Study of PD-001 (Patented Reformulated Cepharanthine) to Support Use in Phase 1 Study for Viral Infectious Diseases

Thu, 31 Oct 2024 08:58:00 -0400

Toronto, Ontario--(Newsfile Corp. - October 31, 2024) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics and previously approved drugs, is announcing it has successfully completed its stability study of its patented enteric-coated cepharanthine formulation ("PD-001"), which supports the manufacturing of...